Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

488
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
488

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From valve prosthesis to coronary artery: a fatal thrombus: a case report.

European heart journal. Case reports·2026
Same author

Early lung ultrasound for clinical risk stratification in acute coronary syndrome: a prospective cohort study.

Heart and vessels·2026
Same author

Assessing Risk of Bloodstream Infections in Patients With Cardiovascular Devices: From Endocarditis to Cardiovascular Infections Team.

The Canadian journal of cardiology·2025
Same author

Focal Takotsubo syndrome: Clinical features and outcomes.

International journal of cardiology·2025
Same author

Takotsubo Syndrome in the Setting of Pacemaker Implantation: Results From a Multicenter National Prospective Registry.

Reviews in cardiovascular medicine·2025
Same author

Age-related differences in cardiogenic shock secondary to Takotsubo syndrome.

European journal of clinical investigation·2025

Related Experiment Video

Updated: Jun 23, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.4K

Timing of P2Y12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI.

Manuel Almendro-Delia1, Begoña Hernández-Meneses1, Gloria Padilla-Rodríguez1

  • 1Acute Cardiovascular Care Unit, Hospital Universitario Virgen Macarena, Seville, Spain.

Journal of the American College of Cardiology
|June 19, 2024
PubMed
Summary

Pretreating ST-segment elevation myocardial infarction (STEMI) patients with P2Y12 inhibitors before angiography significantly reduces major adverse cardiac events (MACE) within 30 days. This pretreatment strategy also avoids increasing bleeding risk, offering a net clinical benefit.

Keywords:
P2Y(12) receptor antagonistSTEMIpretreatmentprimary PCI

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.9K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Related Experiment Videos

Last Updated: Jun 23, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.9K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • The optimal timing for administering P2Y12 inhibitors in ST-segment elevation myocardial infarction (STEMI) patients remains unclear.
  • This study investigates the safety and efficacy of P2Y12 inhibitor pretreatment in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Purpose of the Study:

  • To assess the impact of P2Y12 inhibitor pretreatment on major adverse cardiac events (MACE), major bleeding, and net adverse clinical events (NACE) within 30 days.
  • To evaluate the association between P2Y12 inhibitor pretreatment and clinical outcomes in a regional STEMI network.

Main Methods:

  • Analysis of a prospective multicenter registry including 1,624 STEMI patients.
  • Pretreatment defined as P2Y12 inhibitor administration before coronary angiography.
  • Propensity score analysis with doubly robust weighted estimators to adjust for confounding factors.

Main Results:

  • P2Y12 inhibitor pretreatment was associated with a reduced risk of MACE (adjusted HR: 0.53) and superior net clinical benefit (adjusted HR: 0.47).
  • No significant increase in major bleeding risk was observed with pretreatment (adjusted HR: 0.62).
  • The benefits of pretreatment on MACE were time-dependent, becoming apparent when the interval between administration and PCI exceeded 80 minutes.

Conclusions:

  • Pretreatment with P2Y12 inhibitors in STEMI patients transferred for primary PCI is associated with a time-dependent reduction in 30-day MACE.
  • This strategy does not increase bleeding risk, leading to improved net clinical outcomes.
  • The findings highlight the importance of timing in P2Y12 inhibitor administration for STEMI management.